GoAI
Get started
Profound Medical Corp. logo

Profound Medical Corp.

PROF

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$6.79

+$0.14 · +2.11%

Aug 21, 4:00 PM ET

PROF company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

66

Undervalued

Momentum

50

Neutral

Sentiment

43

Mixed

Risk resilience

55

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
CA
CEO
Arun Swarup Menawat
Listed since
Oct 29, 2019
Employees
162

Market position

Day range

Current $6.79

52-week range

Current $6.79

Open
$6.955
Previous close
$6.65
Volume
74.85K
0.84× average
Average volume
89.26K
Average daily volume
Market cap
246.73M USD
Beta
0.53
Market reference 1
50-day average
$7.0159
-3.22% below average
200-day average
$6.8725
-1.20% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
162.59M USD
P/E (TTM)
-6.97×
P/B (TTM)
4.94×
P/S (TTM)
12.95×
EV / EBITDA
-3.93×
Earnings yield
-18.20%
Free cash flow yield
-16.41%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
71.73%
Operating margin
-184.35%
Net margin
-170.92%
Return on equity
-47.60%
Return on assets
-22.45%
Return on invested capital
-22.70%

Financial health

Debt / equity
0.15×
Current ratio
12.52×
Altman Z-score
8.85
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends126%-95%-315%-536%Gross margin, FY2021: 42.95%Gross margin, FY2022: 45.22%Gross margin, FY2023: 60.87%Gross margin, FY2024: 65.89%Gross margin, FY2025: 70.77%Operating margin, FY2021: -440.72%Operating margin, FY2022: -480.86%Operating margin, FY2023: -397.50%Operating margin, FY2024: -309.57%Operating margin, FY2025: -256.27%Net margin, FY2021: -446.66%Net margin, FY2022: -429.11%Net margin, FY2023: -396.85%Net margin, FY2024: -260.45%Net margin, FY2025: -264.44%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 42.95%. Gross margin FY2022 45.22%. Gross margin FY2023 60.87%. Gross margin FY2024 65.89%. Gross margin FY2025 70.77%. Operating margin FY2021 -440.72%. Operating margin FY2022 -480.86%. Operating margin FY2023 -397.50%. Operating margin FY2024 -309.57%. Operating margin FY2025 -256.27%. Net margin FY2021 -446.66%. Net margin FY2022 -429.11%. Net margin FY2023 -396.85%. Net margin FY2024 -260.45%. Net margin FY2025 -264.44%.

Income trends

Revenue

16.38M USD+61.10%

Operating income

−41.98M USD-33.37%

Net income

−43.32M USD-63.57%
Income trends across reported periods22.35M USD−1.53M USD−25.41M USD−49.28M USDRevenue, FY2021: 6.87M USDRevenue, FY2022: 6.68M USDRevenue, FY2023: 7.2M USDRevenue, FY2024: 10.17M USDRevenue, FY2025: 16.38M USDOperating income, FY2021: −30.29M USDOperating income, FY2022: −32.13M USDOperating income, FY2023: −28.62M USDOperating income, FY2024: −31.47M USDOperating income, FY2025: −41.98M USDNet income, FY2021: −30.7M USDNet income, FY2022: −28.67M USDNet income, FY2023: −28.57M USDNet income, FY2024: −26.48M USDNet income, FY2025: −43.32M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 6.87M USD. Revenue FY2022 6.68M USD. Revenue FY2023 7.2M USD. Revenue FY2024 10.17M USD. Revenue FY2025 16.38M USD. Operating income FY2021 −30.29M USD. Operating income FY2022 −32.13M USD. Operating income FY2023 −28.62M USD. Operating income FY2024 −31.47M USD. Operating income FY2025 −41.98M USD. Net income FY2021 −30.7M USD. Net income FY2022 −28.67M USD. Net income FY2023 −28.57M USD. Net income FY2024 −26.48M USD. Net income FY2025 −43.32M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue16.38M USD10.17M USD7.2M USD6.68M USD6.87M USD
Cost of goods sold4.79M USD3.47M USD2.82M USD3.66M USD3.92M USD
Gross profit11.59M USD6.7M USD4.38M USD3.02M USD2.95M USD
Research and development20.96M USD16.15M USD14.38M USD14.69M USD15.28M USD
Selling, general, and administrative32.61M USD22.02M USD18.62M USD17.93M USD17.97M USD
Operating expenses53.57M USD38.17M USD33M USD35.15M USD33.24M USD
Interest income1.09M USD1.37M USD1.64M USD1.05M USD203.2K USD
Interest expense——770K USD167.11K USD66.41K USD
Depreciation and amortization569.8K USD891.06K USD1.15M USD1.6M USD1.88M USD
Operating income−41.98M USD−31.47M USD−28.62M USD−32.13M USD−30.29M USD
Net income−43.32M USD−26.48M USD−28.57M USD−28.67M USD−30.7M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 5 misses, 1 met estimate
Average EPS surprise
-1.50%
11 comparable reports
Latest EPS result
-0.26
Estimate -0.22 · Miss by 18.18%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.16-0.29-0.43-0.56Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MetQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual -0.2, estimate -0.31, surprise +35.48%, Beat. Q2 2025, reported May 8, 2025: actual -0.36, estimate -0.29, surprise -24.14%, Miss. Q3 2025, reported Aug 14, 2025: actual -0.52, estimate -0.43, surprise -20.93%, Miss. Q4 2025, reported Nov 13, 2025: actual -0.26, estimate -0.38, surprise +31.58%, Beat. Q1 2026, reported Mar 5, 2026: actual -0.27, estimate -0.27, surprise 0.00%, Met estimate. Q2 2026, reported May 7, 2026: actual -0.19, estimate -0.24, surprise +20.83%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.26, estimate -0.22, surprise -18.18%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.23, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates11.19M8.09M4.98M1.88MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual 5.33M USD, estimate 5.92M USD, surprise -9.99%, Miss. Q2 2025, reported May 8, 2025: actual 2.62M USD, estimate 4.69M USD, surprise -44.12%, Miss. Q3 2025, reported Aug 14, 2025: actual 2.21M USD, estimate 4.73M USD, surprise -53.29%, Miss. Q4 2025, reported Nov 13, 2025: actual 5.23M USD, estimate 10.53M USD, surprise -50.31%, Miss. Q1 2026, reported Mar 5, 2026: actual 5.98M USD, estimate 7.67M USD, surprise -22.04%, Miss. Q2 2026, reported May 7, 2026: actual 5.34M USD, estimate 4.85M USD, surprise +10.00%, Beat. Q3 2026, reported Aug 6, 2026: actual 2.48M USD, estimate 4.75M USD, surprise -47.73%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 6.85M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$11.00

62.00% upside
Past 12 months12-month forecastHigh $11.00Average $11.00Low $11.00

Rating distribution

7 ratings
Strong buy00%
Buy686%
Hold114%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions

PROF news

globenewswire.com

Profound's Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days'

Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day Most recent TDC software provides a potential roadmap for customers to easily achieve up…

Read source
globenewswire.com

Profound Medical Announces Management Change

TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI…

Read source
globenewswire.com

Profound Medical Launches ‘Let's Huddle', a Global Community Supporting Men Throughout Their Prostate Care Journey

A patient-centered initiative focused on education, connection, and support A patient-centered initiative focused on education, connection, and support

Read source
marketbeat.com

Profound Medical Q2 Earnings Call Highlights

Profound Medical NASDAQ: PROF reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing of TULSA product…

Read source
zacks.com

Profound Medical (PROF) Q2 Earnings Surpass Estimates

Profound Medical (PROF) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.52 per share a year ago.

Read source
globenewswire.com

Profound Medical Reports Second Quarter 2026 Financial Results

– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, commercial and…

Read source

PROF peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PROF

Funds reporting this stock among their holdings, ordered by reported position size.

Invesco NASDAQ Future Gen 200 ETF logoInvesco NASDAQ Future Gen 200 ETFQQQS
Market value
109.33K
Weight
0.48%
AUM
22.98M USD
Expense ratio
0.20%
Price / 1D
$45.0826+1.10%
Dimensional - International Core Equity 2 ETF logoDimensional - International Core Equity 2 ETFDFIC
Market value
12.58K
Weight
0.00%
AUM
15.43B USD
Expense ratio
0.22%
Price / 1D
$39.405+0.83%

Continue in GoAI

Research PROF

research.disclaimer